Research on Targeted Therapy for Malignant Tumors of the Biliary Tract

Area of Science:

• Oncology
• Genetics

Background:

• Biliary tract cancers (BTCs) are aggressive malignancies with increasing incidence and poor prognoses.
• Current management often involves traditional chemotherapy with limited efficacy.

Purpose of the Study:

• To review advances in precision oncology and immunotherapy for BTC management.
• To highlight the impact of genomic profiling on treatment strategies.

Main Methods:

• Systematic review of recent literature on precision oncology and immunotherapy in BTC.
• Analysis of genomic alterations and their corresponding targeted therapies.
• Evaluation of emerging immunotherapeutic approaches.

Main Results:

• Genomic profiling identified targetable alterations (e.g., IDH1/2, FGFR2, HER2, BRAF V600E) driving success with specific inhibitors.
• Targeted agents demonstrated superior response rates and survival benefits in molecularly selected BTC populations compared to chemotherapy.
• Immunotherapies, including checkpoint inhibitors, show promise, particularly in MSI-H/dMMR tumors, and may synergize with targeted treatments.

Conclusions:

• A paradigm shift towards molecularly guided therapies is improving BTC patient survival.
• Overcoming tumor heterogeneity and resistance mechanisms are key challenges for future research.
• Combination strategies involving targeted therapies and immunotherapies hold significant therapeutic potential.